These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11135508)

  • 21. Editorial: Challenges to Opioid Use Disorders During COVID-19.
    Sun Y; Bao Y; Kosten T; Strang J; Shi J; Lu L
    Am J Addict; 2020 May; 29(3):174-175. PubMed ID: 32281130
    [No Abstract]   [Full Text] [Related]  

  • 22. Dose Tapering Strategy for Heroin Abstinence among Methadone Maintenance Treatment Participants: Evidence from A Retrospective Study in Guangdong, China.
    Lu Q; Zou X; Liu Y; Gong C; Ling L
    Int J Environ Res Public Health; 2019 Aug; 16(15):. PubMed ID: 31390750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.
    Stein MD; Conti MT; Herman DS; Anderson BJ; Bailey GL; Noppen DV; Abrantes AM
    Am J Addict; 2019 Jul; 28(4):270-276. PubMed ID: 30993833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.
    Weinstein ZM; Gryczynski G; Cheng DM; Quinn E; Hui D; Kim HW; Labelle C; Samet JH
    Drug Alcohol Depend; 2018 Aug; 189():166-171. PubMed ID: 29958128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "It Ruined My Life": The effects of the War on Drugs on people who inject drugs (PWID) in rural Puerto Rico.
    Abadie R; Gelpi-Acosta C; Davila C; Rivera A; Welch-Lazoritz M; Dombrowski K
    Int J Drug Policy; 2018 Jan; 51():121-127. PubMed ID: 28716395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "I Was Not Sick and I Didn't Need to Recover": Methadone Maintenance Treatment (MMT) as a Refuge from Criminalization.
    Frank D
    Subst Use Misuse; 2018 Jan; 53(2):311-322. PubMed ID: 28704148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pain in the management of opioid use disorder.
    Sirohi S; Tiwari AK
    J Pain Res; 2016; 9():963-966. PubMed ID: 27853389
    [No Abstract]   [Full Text] [Related]  

  • 28. The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature.
    Ramsey SE; Rounsaville D; Hoskinson R; Park TW; Ames EG; Neirinckx VD; Friedmann P
    Subst Abuse; 2016; 10():65-8. PubMed ID: 27512336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?
    Blum K; Gold M; Clark HW; Dushaj K; Badgaiyan RD
    Subst Use Misuse; 2016 Oct; 51(12):1674-1679. PubMed ID: 27462930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Prospective Study to Investigate Predictors of Relapse among Patients with Opioid Use Disorder Treated with Methadone.
    Naji L; Dennis BB; Bawor M; Plater C; Pare G; Worster A; Varenbut M; Daiter J; Marsh DC; Desai D; Thabane L; Samaan Z
    Subst Abuse; 2016; 10():9-18. PubMed ID: 27103815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenging biopower: "Liquid cuffs" and the "Junkie" habitus.
    Gelpi-Acosta C
    Drugs (Abingdon Engl); 2014 Dec; 22(3):248-254. PubMed ID: 26962271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid tolerance in methadone maintenance treatment: comparison of methadone and levomethadone in long-term treatment.
    Gutwinski S; Schoofs N; Stuke H; Riemer TG; Wiers CE; Bermpohl F
    Harm Reduct J; 2016 Feb; 13():7. PubMed ID: 26879120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.
    Monico LB; Gryczynski J; Mitchell SG; Schwartz RP; O'Grady KE; Jaffe JH
    J Subst Abuse Treat; 2015 Oct; 57():89-95. PubMed ID: 25986647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can we bottle psychosocial treatments for addiction? The role of oxytocin.
    Stauffer CS; Woolley JD
    J Clin Psychiatry; 2014 Sep; 75(9):1028-9. PubMed ID: 25295428
    [No Abstract]   [Full Text] [Related]  

  • 35. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
    Nielsen S; Hillhouse M; Mooney L; Ang A; Ling W
    J Subst Abuse Treat; 2015 Jan; 48(1):70-6. PubMed ID: 25065489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system.
    Chartoff EH; Connery HS
    Front Pharmacol; 2014; 5():116. PubMed ID: 24904419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leaving buprenorphine treatment: patients' reasons for cessation of care.
    Gryczynski J; Mitchell SG; Jaffe JH; O'Grady KE; Olsen YK; Schwartz RP
    J Subst Abuse Treat; 2014 Mar; 46(3):356-61. PubMed ID: 24238714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retention in methadone and buprenorphine treatment among African Americans.
    Gryczynski J; Mitchell SG; Jaffe JH; Kelly SM; Myers CP; O'Grady KE; Olsen YK; Schwartz RP
    J Subst Abuse Treat; 2013 Sep; 45(3):287-92. PubMed ID: 23566446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methadone treatments in a Swiss region, 2001-2008: a registry-based analysis.
    Huissoud T; Rousson V; Dubois-Arber F
    BMC Psychiatry; 2012 Dec; 12():238. PubMed ID: 23270305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.
    Matusow H; Dickman SL; Rich JD; Fong C; Dumont DM; Hardin C; Marlowe D; Rosenblum A
    J Subst Abuse Treat; 2013; 44(5):473-80. PubMed ID: 23217610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.